Molecular signatures of obstructive sleep apnea in adults: A review and perspective

Sleep

Volumn 32, Issue 4, 2009, Pages 447-470

  Arnardottir, Erna S ^a,b,c   Mackiewicz, Miroslaw ^a   Gislason, Thorarinn ^b,c   Teff, Karen L ^d,e   Pack, Allan I ^a,c  

^a Center for Sleep and Respiratory Neurobiology   (United States)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^c UNIVERSITY OF ICELAND   (Iceland)

^d MONELL CHEMICAL SENSES CENTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chronic intermittent hypoxia; Molecular mechanisms; Obstructive sleep apnea; Pathophysiology; Sleep fragmentation

Indexed keywords

8 ISOPROSTANE; ADIPONECTIN; C REACTIVE PROTEIN; FATTY ACID; GRANULOCYTE CHEMOTACTIC PROTEIN 2; HEPCIDIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; MALONALDEHYDE; MESSENGER RNA; PROTEIN; REACTIVE OXYGEN METABOLITE; RESISTIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA;

BLOOD ANALYSIS; COMORBIDITY; CYTOKINE PRODUCTION; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; HUMAN; INFLAMMATION; INFLAMMATORY INFILTRATE; LIPID PEROXIDATION; METABOLITE; MICROARRAY ANALYSIS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEOMICS; REVIEW; RISK FACTOR; SLEEP APNEA SYNDROME; SYMPATHETIC TONE; THORAX PRESSURE; URINALYSIS;

EID: 65249155915     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.1093/sleep/32.4.447     Document Type: Review

References (528)

1. Kittleson MM, Hare JM. Molecular signature analysis: using the myocardial transcriptome as a biomarker in cardiovascular disease. Trends Cardiovasc Med 2005;15:130-8.
2. Mohr S, Liew CC. The peripheral-blood transcriptome: new insights into disease and risk assessment. Trends Mol Med 2007;13:422-32.
3. Rockett JC, Burczynski ME, Fornace AJ, Herrmann PC, Krawetz SA, Dix DJ. Surrogate tissue analysis: monitoring toxicant exposure and health status of inaccessible tissues through the analysis of accessible tissues and cells. Toxicol Appl Pharmacol 2004;194:189-99.
4. Barratt J, Topham P. Urine proteomics: the present and future of measuring urinary protein components in disease. CMAJ 2007;177:361-8.
5. Hakonarson H, Bjornsdottir US, Halapi E, et al. Profling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients. Proc Natl Acad Sci U S A 2005;102:14789-94.
6. Scarpelli D, Cardellini M, Andreozzi F, et al. Variants of the interleukin-10 promoter gene are associated with obesity and insulin resistance but not type 2 diabetes in caucasian italian subjects. Diabetes 2006;55:1529-33.
7. Lemaitre RN, Heckbert SR, Sotoodehnia N, et al. beta1- and beta2-Adrenergic receptor gene variation, beta-blocker use and risk of myocardial infarction and stroke. Am J Hypertens 2008;21:290-6.
8. Shearman AM, Cooper JA, Kotwinski PJ, et al. Estrogen receptor alpha gene variation is associated with risk of myocardial infarction in more than seven thousand men from fve cohorts. Circ Res 2006;98:590-2.
9. Bohen SP, Troyanskaya OG, Alter O, et al. Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci U S A 2003;100:1926-30.
10. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
11. Kittleson MM, Minhas KM, Irizarry RA, et al. Gene expression analysis of ischemic and nonischemic cardiomyopathy: shared and distinct genes in the development of heart failure. Physiol Genomics 2005;21:299-307.
12. Tsiotra PC, Tsigos C, Yfanti E, et al. Visfatin, TNF-alpha and IL-6 mRNA expression is increased in mononuclear cells from type 2 diabetic women. Horm Metab Res 2007;39:758-63.
13. Lupattelli G, Marchesi S, Ronti T, et al. Endothelial dysfunction in vivo is related to monocyte resistin mRNA expression. J Clin Pharm Ther 2007;32:373-9.
14. de Mello VD, Kolehmainen M, Schwab U, et al. Effect of weight loss on cytokine messenger RNA expression in peripheral blood mononuclear cells of obese subjects with the metabolic syndrome. Metabolism 2008;57:192-9.
15. Greenberg H, Ye X, Wilson D, Htoo AK, Hendersen T, Liu SF. Chronic intermittent hypoxia activates nuclear factor-kappaB in cardiovascular tissues in vivo. Biochem Biophys Res Commun 2006;343:591-6.
16. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinfammatory state. Circulation 2004;110:1564-71.
17. Yndestad A, Holm AM, Muller F, et al. Enhanced expression of infammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc Res 2003;60:141-6.
18. Schulz R, Mahmoudi S, Hattar K, et al. Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med 2000;162:566-70.
19. Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med 2002;165:934-9.
20. Foldes G, von Haehling S, Okonko DO, Jankowska EA, Poole- Wilson PA, Anker SD. Fluvastatin reduces increased blood monocyte Toll-like receptor 4 expression in whole blood from patients with chronic heart failure. Int J Cardiol 2008;124:80-5.
21. Yamauchi M, Tamaki S, Tomoda K, et al. Evidence for activation of nuclear factor kappaB in obstructive sleep apnea. Sleep Breath 2006;10:189-93.
22. Tang Y, Lu A, Aronow BJ, Wagner KR, Sharp FR. Genomic responses of the brain to ischemic stroke, intracerebral haemorrhage, kainate seizures, hypoglycemia, and hypoxia. Eur J Neurosci 2002;15:1937-52.
23. Tang Y, Lu A, Aronow BJ, Sharp FR. Blood genomic responses differ after stroke, seizures, hypoglycemia, and hypoxia: blood genomic fngerprints of disease. Ann Neurol 2001;50:699-707.
24. Hoffmann MS, Singh P, Wolk R, Romero-Corral A, Raghavakaimal S, Somers VK. Microarray studies of genomic oxidative stress and cell cycle responses in obstructive sleep apnea. Antioxid Redox Signal 2007;9:661-9.
25. Mackiewicz M, Shockley KR, Romer MA, et al. Macromolecule biosynthesis: a key function of sleep. Physiol Genomics 2007;31:441-57.
26. Zimmerman JE, Rizzo W, Shockley KR, et al. Multiple mechanisms limit the duration of wakefulness in Drosophila brain. Physiol Genomics 2006;27:337-50.
27. Du X, Tang Y, Xu H, et al. Genomic profles for human peripheral blood T cells, B cells, natural killer cells, monocytes, and polymorphonuclear cells: comparisons to ischemic stroke, migraine, and Tourette syndrome. Genomics 2006;87:693-703.
28. Ardigo D, Gaillard CA, Braam B. Application of leukocyte transcriptomes to assess systemic consequences of risk factors for cardiovascular disease. Clin Chem Lab Med 2007;45:1109-20.
29. Basheer R, Brown R, Ramesh V, Begum S, McCarley RW. Sleep deprivation-induced protein changes in basal forebrain: implications for synaptic plasticity. J Neurosci Res 2005;82:650-8.
30. Klein JB, Gozal D, Pierce WM, et al. Proteomic identifcation of a novel protein regulated in CA1 and CA3 hippocampal regions during intermittent hypoxia. Respir Physiol Neurobiol 2003;136:91-103.
31. Krishna J, Shah ZA, Merchant M, Klein JB, Gozal D. Urinary protein expression patterns in children with sleep-disordered breathing: preliminary fndings. Sleep Med 2006;7:221-7.
32. Shah ZA, Jortani SA, Tauman R, Valdes R, Jr., Gozal D. Serum proteomic patterns associated with sleep-disordered breathing in children. Pediatr Res 2006;59:466-70.
33. Koopmann J, Zhang Z, White N, et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004;10:860-8.
34. Kang X, Xu Y, Wu X, et al. Proteomic fngerprints for potential application to early diagnosis of severe acute respiratory syndrome. Clin Chem 2005;51:56-64.
35. Pawlyk AC, Ferber M, Shah A, Pack AI, Naidoo N. Proteomic analysis of the effects and interactions of sleep deprivation and aging in mouse cerebral cortex. J Neurochem 2007;103:2301-13.
36. Pisitkun T, Johnstone R, Knepper MA. Discovery of urinary biomarkers. Mol Cell Proteomics 2006;5:1760-71.
37. Meyer HE, Stuhler K. High-performance proteomics as a tool in biomarker discovery. Proteomics 2007;7 Suppl 1:18-26.
38. Sabatine MS, Liu E, Morrow DA, et al. Metabolomic identifcation of novel biomarkers of myocardial ischemia. Circulation 2005;112:3868-75.
39. Wang C, Kong H, Guan Y, et al. Plasma phospholipid metabolic profling and biomarkers of type 2 diabetes mellitus based on high-performance liquid chromatography/electrospray mass spectrometry and multivariate statistical analysis. Anal Chem 2005;77:4108-16.
40. Yang J, Xu G, Hong Q, et al. Discrimination of Type 2 diabetic patients from healthy controls by using metabonomics method based on their serum fatty acid profles. J Chromatogr B Analyt Technol Biomed Life Sci 2004;813:53-8.
41. Schnackenberg LK, Beger RD. Monitoring the health to disease continuum with global metabolic profling and systems biology. Pharmacogenomics 2006;7:1077-86.
42. Weckwerth W, Morgenthal K. Metabolomics: from pattern recognition to biological interpretation. Drug Discov Today 2005;10:1551-8.
43. Bell J. Predicting disease using genomics. Nature 2004;429:453-6.
44. Ginsburg GS, Donahue MP, Newby LK. Prospects for personalized cardiovascular medicine: the impact of genomics. J Am Coll Cardiol 2005;46:1615-27.
45. Lango H, Weedon MN. What will whole genome searches for susceptibility genes for common complex disease offer to clinical practice? J Intern Med 2008;263:16-27.
46. Arnett DK, Baird AE, Barkley RA, et al. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientifc statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2007;115:2878-901.
47. Caples SM, Gami AS, Somers VK. Obstructive sleep apnea. Ann Intern Med 2005;142:187-97.
48. Pack AI. Advances in sleep-disordered breathing. Am J Respir Crit Care Med 2006;173:7-15.
49. Barbe F, Mayoralas LR, Duran J, et al. Treatment with continuous positive airway pressure is not effective in patients with sleep apnea but no daytime sleepiness. a randomized, controlled trial. Ann Intern Med 2001;134:1015-23.
50. Thorpy MJ. The clinical use of the Multiple Sleep Latency Test. The Standards of Practice Committee of the American Sleep Disorders Association. Sleep 1992;15:268-76.
51. Carskadon MA, Dement WC, Mitler MM, Roth T, Westbrook PR, Keenan S. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep 1986;9:519-24.
52. Littner MR, Kushida C, Wise M, et al. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep 2005;28:113-21.
53. Doghramji K, Mitler MM, Sangal RB, et al. A normative study of the maintenance of wakefulness test (MWT). Electroencephalogr Clin Neurophysiol 1997;103:554-62.
54. Lim J, Dinges DF. Sleep deprivation and vigilant attention. Ann N Y Acad Sci 2008;1129:305-22.
55. Dinges DF, Powell JW. Microcomputer analyses of performance on a portable, simple visual RT task during sustained operations. Behav Res Meth Instr Comp 1985;17:652-5.
56. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-5.
57. Johns MW. Daytime sleepiness, snoring, and obstructive sleep apnea. The Epworth Sleepiness Scale. Chest 1993;103:30-6.
58. Johns MW. Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep 1992;15:376-81.
59. Kaida K, Takahashi M, Akerstedt T, et al. Validation of the Karolinska sleepiness scale against performance and EEG variables. Clin Neurophysiol 2006;117:1574-81.
60. Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000;283:1829-36.
61. Lavie P, Herer P, Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. BMJ 2000;320:479-82.
62. Bixler EO, Vgontzas AN, Lin HM, et al. Association of hypertension and sleep-disordered breathing. Arch Intern Med 2000;160:2289-95.
63. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000;342:1378-84.
64. Peker Y, Hedner J, Norum J, Kraiczi H, Carlson J. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up. Am J Respir Crit Care Med 2002;166:159-65.
65. Peker Y, Kraiczi H, Hedner J, Loth S, Johansson A, Bende M. An independent association between obstructive sleep apnoea and coronary artery disease. Eur Respir J 1999;14:179-84.
66. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005;353:2034-41.
67. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005;365:1046-53.
68. Munoz R, Duran-Cantolla J, Martinez-Vila E, et al. Severe sleep apnea and risk of ischemic stroke in the elderly. Stroke 2006;37:2317-21.
69. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;328:1230-5.
70. Ip MS, Lam KS, Ho C, Tsang KW, Lam W. Serum leptin and vascular risk factors in obstructive sleep apnea. Chest 2000;118:580-6.
71. Ciftci TU, Kokturk O, Bukan N, Bilgihan A. The relationship between serum cytokine levels with obesity and obstructive sleep apnea syndrome. Cytokine 2004;28:87-91.
72. El-Solh AA, Mador MJ, Sikka P, Dhillon RS, Amsterdam D, Grant BJ. Adhesion molecules in patients with coronary artery disease and moderate-to-severe obstructive sleep apnea. Chest 2002;121:1541-7.
73. Barcelo A, Barbe F, Llompart E, et al. Effects of obesity on C- reactive protein level and metabolic disturbances in male patients with obstructive sleep apnea. Am J Med 2004;117:118-21.
74. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab 1997;82:1313-6.
75. Imagawa S, Yamaguchi Y, Ogawa K, et al. Interleukin-6 and tumor necrosis factor-alpha in patients with obstructive sleep apnea-hypopnea syndrome. Respiration 2004;71:24-9.
76. Khalyfa A, Capdevila OS, Buazza MO, Serpero LD, Kheirandish-Gozal L, Gozal D. Genome-wide gene expression profling in children with non-obese obstructive sleep apnea. Sleep Med 2008 Feb 6 [Epub ahead of print].
77. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002;165:1217-39.
78. McNicholas WT, Bonsigore MR. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J 2007;29:156- 78.
79. Sullivan CE, Issa FG, Berthon-Jones M, Eves L. Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares. Lancet 1981;1:862-5.
80. Jenkinson C, Davies RJ, Mullins R, Stradling JR. Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised prospective parallel trial. Lancet 1999;353:2100-5.
81. Giles TL, Lasserson TJ, Smith BJ, White J, Wright J, Cates CJ. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2006:CD001106.
82. Meurice JC, Dore P, Paquereau J, et al. Predictive factors of longterm compliance with nasal continuous positive airway pressure treatment in sleep apnea syndrome. Chest 1994;105:429-33.
83. Weaver TE, Maislin G, Dinges DF, et al. Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning. Sleep 2007;30:711-9.
84. Effros RM, Dunning MB 3rd, Biller J, Shaker R. The promise and perils of exhaled breath condensates. Am J Physiol Lung Cell Mol Physiol 2004;287:L1073-80.
85. Ryan S, Taylor CT, McNicholas WT. Predictors of elevated nuclear factor-kappaB-dependent genes in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2006;174:824-30.
86. Jordan W, Cohrs S, Degner D, et al. Evaluation of oxidative stress measurements in obstructive sleep apnea syndrome. J Neural Transm 2006;113:239-54.
87. Chin K, Ohi M, Shimizu K, Nakamura T, Miyaoka F, Mishima M. Increase in bilirubin levels of patients with obstructive sleep apnea in the morning--a possible explanation of induced heme oxygenase-1. Sleep 2001;24:218-23.
88. Alberti A, Sarchielli P, Gallinella E, Floridi A, Mazzotta G, Gallai V. Plasma cytokine levels in patients with obstructive sleep apnea syndrome: a preliminary study. J Sleep Res 2003;12:305-11.
89. Sonka K, Kelemen J, Kemlink D, et al. Evening and morning plasma levels of protein S100B in patients with obstructive sleep apnea. Neuro Endocrinol Lett 2007;28:575-9.
90. Carpagnano GE, Kharitonov SA, Resta O, Foschino-Barbaro MP, Gramiccioni E, Barnes PJ. Increased 8-isoprostane and interleukin-6 in breath condensate of obstructive sleep apnea patients. Chest 2002;122:1162-7.
91. Carpagnano GE, Kharitonov SA, Resta O, Foschino-Barbaro MP, Gramiccioni E, Barnes PJ. 8-Isoprostane, a marker of oxidative stress, is increased in exhaled breath condensate of patients with obstructive sleep apnea after night and is reduced by continuous positive airway pressure therapy. Chest 2003;124:1386-92.
92. Lavie L. Sleep-disordered breathing and cerebrovascular disease: a mechanistic approach. Neurol Clin 2005;23:1059-75.
93. Chiang AA. Obstructive sleep apnea and chronic intermittent hypoxia: a review. Chin J Physiol 2006;49:234-43.
94. Prabhakar NR, Kumar GK, Nanduri J, Semenza GL. ROS signaling in systemic and cellular responses to chronic intermittent hypoxia. Antioxid Redox Signal 2007;9:1397-403.
95. Semenza GL, Prabhakar NR. HIF-1-dependent respiratory, cardiovascular, and redox responses to chronic intermittent hypoxia. Antioxid Redox Signal 2007;9:1391-6.
96. Fletcher EC, Lesske J, Qian W, Miller CC 3rd, Unger T. Repetitive, episodic hypoxia causes diurnal elevation of blood pressure in rats. Hypertension 1992;19:555-61.
97. Fletcher EC, Lesske J, Behm R, Miller CC 3rd, Stauss H, Unger T. Carotid chemoreceptors, systemic blood pressure, and chronic episodic hypoxia mimicking sleep apnea. J Appl Physiol 1992;72:1978-84.
98. Lesske J, Fletcher EC, Bao G, Unger T. Hypertension caused by chronic intermittent hypoxia--infuence of chemoreceptors and sympathetic nervous system. J Hypertens 1997;15:1593-603.
99. Gozal D, Row BW, Kheirandish L, et al. Increased susceptibility to intermittent hypoxia in aging rats: changes in proteasomal activity, neuronal apoptosis and spatial function. J Neurochem 2003;86:1545-52.
100. Li RC, Row BW, Gozal E, et al. Cyclooxygenase 2 and intermittent hypoxia-induced spatial defcits in the rat. Am J Respir Crit Care Med 2003;168:469-75.
101. Row BW, Goldbart A, Gozal E, Gozal D. Spatial pre-training attenuates hippocampal impairments in rats exposed to intermittent hypoxia. Neurosci Lett 2003;339:67-71.
102. Chen L, Einbinder E, Zhang Q, Hasday J, Balke CW, Scharf SM. Oxidative stress and left ventricular function with chronic intermittent hypoxia in rats. Am J Respir Crit Care Med 2005;172:915- 20.
103. Kheirandish L, Row BW, Li RC, Brittian KR, Gozal D. Apolipoprotein E-defcient mice exhibit increased vulnerability to intermittent hypoxia-induced spatial learning defcits. Sleep 2005;28:1412-7.
104. Goldbart AD, Row BW, Kheirandish-Gozal L, Cheng Y, Brittian KR, Gozal D. High fat/refned carbohydrate diet enhances the susceptibility to spatial learning defcits in rats exposed to intermittent hypoxia. Brain Res 2006;1090:190-6.
105. Kumar GK, Rai V, Sharma SD, et al. Chronic intermittent hypoxia induces hypoxia-evoked catecholamine effux in adult rat adrenal medulla via oxidative stress. J Physiol 2006;575:229-39.
106. Row BW, Kheirandish L, Cheng Y, Rowell PP, Gozal D. Impaired spatial working memory and altered choline acetyltransferase (CHAT) immunoreactivity and nicotinic receptor binding in rats exposed to intermittent hypoxia during sleep. Behav Brain Res 2007;177:308-14.
107. Zoccal DB, Bonagamba LG, Oliveira FR, Antunes-Rodrigues J, Machado BH. Increased sympathetic activity in rats submitted to chronic intermittent hypoxia. Exp Physiol 2007;92:79-85.
108. Zhan G, Fenik P, Pratico D, Veasey SC. Inducible nitric oxide synthase in long-term intermittent hypoxia: hypersomnolence and brain injury. Am J Respir Crit Care Med 2005;171:1414-20.
109. Zhan G, Serrano F, Fenik P, et al. NADPH oxidase mediates hypersomnolence and brain oxidative injury in a murine model of sleep apnea. Am J Respir Crit Care Med 2005;172:921-9.
110. Polotsky V Y, Li J, Punjabi NM, et al. Intermittent hypoxia increases insulin resistance in genetically obese mice. J Physiol (Lond) 2003;552:253-64.
111. Veasey SC, Davis CW, Fenik P, et al. Long-term intermittent hypoxia in mice: protracted hypersomnolence with oxidative injury to sleep-wake brain regions. Sleep 2004;27:194-201.
112. Xu W, Chi L, Row BW, et al. Increased oxidative stress is associated with chronic intermittent hypoxia-mediated brain cortical neuronal cell apoptosis in a mouse model of sleep apnea. Neuroscience 2004;126:313-23.
113. Peng YJ, Yuan G, Ramakrishnan D, et al. Heterozygous HIF-1alpha defciency impairs carotid body-mediated systemic responses and reactive oxygen species generation in mice exposed to intermittent hypoxia. J Physiol 2006;577:705-16.
114. Phillips SA, Olson EB, Lombard JH, Morgan BJ. Chronic intermittent hypoxia alters NE reactivity and mechanics of skeletal muscle resistance arteries. J Appl Physiol 2006;100:1117-23.
115. Iiyori N, Alonso LC, Li J, et al. Intermittent hypoxia causes insulin resistance in lean mice independent of autonomic activity. Am J Respir Crit Care Med 2007;175:851-7.
116. Savransky V, Bevans S, Nanayakkara A, et al. Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver. Am J Physiol Gastrointest Liver Physiol 2007;293:G871-7.
117. Yokoe T, Alonso LC, Romano LC, et al. Intermittent hypoxia reverses the diurnal glucose rhythm and causes pancreatic beta-cell replication in mice. J Physiol 2008;586:899-911.
118. Zhu Y, Fenik P, Zhan G, et al. Selective loss of catecholaminergic wake active neurons in a murine sleep apnea model. J Neurosci 2007;27:10060-71.
119. Dematteis M, Julien C, Guillermet C, et al. Intermittent hypoxia induces early functional cardiovascular remodeling in mice. Am J Respir Crit Care Med 2008;177:227-35.
120. Yuan G, Adhikary G, McCormick AA, Holcroft JJ, Kumar GK, Prabhakar NR. Role of oxidative stress in intermittent hypoxiainduced immediate early gene activation in rat PC12 cells. J Physiol 2004;557:773-83.
121. Ryan S, Taylor CT, McNicholas WT. Selective activation of infammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 2005;112:2660-7.
122. Ryan S, McNicholas WT, Taylor CT. A critical role for p38 map kinase in NF-kappaB signaling during intermittent hypoxia/reoxygenation. Biochem Biophys Res Commun 2007;355:728-33.
123. Shan X, Chi L, Ke Y, et al. Manganese superoxide dismutase protects mouse cortical neurons from chronic intermittent hypoxiamediated oxidative damage. Neurobiol Dis 2007;28:206-15.
124. Fletcher EC, Lesske J, Culman J, Miller CC, Unger T. Sympathetic denervation blocks blood pressure elevation in episodic hypoxia. Hypertension 1992;20:612-9.
125. Yuan G, Nanduri J, Bhasker CR, Semenza GL, Prabhakar NR. Ca2+/calmodulin kinase-dependent activation of hypoxia inducible factor 1 transcriptional activity in cells subjected to intermittent hypoxia. J Biol Chem 2005;280:4321-8.
126. Toffoli S, Feron O, Raes M, Michiels C. Intermittent hypoxia changes HIF-1alpha phosphorylation pattern in endothelial cells: unravelling of a new PKA-dependent regulation of HIF-1alpha. Biochim Biophys Acta 2007;1773:1558-71.
127. Li J, Bosch-Marce M, Nanayakkara A, et al. Altered metabolic responses to intermittent hypoxia in mice with partial defciency of hypoxia-inducible factor-1alpha. Physiol Genomics 2006;25:450-7.
128. Belaidi E, Beguin PC, Levy P, Ribuot C, Godin-Ribuot D. Prevention of HIF-1 activation and iNOS gene targeting by low-dose cadmium results in loss of myocardial hypoxic preconditioning in the rat. Am J Physiol Heart Circ Physiol 2007.
129. Rius J, Guma M, Schachtrup C, et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008;453:807-11.
130. Lam SY, Tipoe GL, Liong EC, Fung ML. Differential expressions and roles of hypoxia-inducible factor-1alpha, -2alpha and -3alpha in the rat carotid body during chronic and intermittent hypoxia. Histol Histopathol 2008;23:271-80.
131. Young T, Evans L, Finn L, Palta M. Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. Sleep 1997;20:705-6.
132. Li J, Thorne LN, Punjabi NM, et al. Intermittent hypoxia induces hyperlipidemia in lean mice. Circ Res 2005;97:698-706.
133. Somers VK, Mark AL, Zavala DC, Abboud FM. Contrasting effects of hypoxia and hypercapnia on ventilation and sympathetic activity in humans. J Appl Physiol 1989;67:2101-6.
134. Somers VK, Mark AL, Zavala DC, Abboud FM. Infuence of ventilation and hypocapnia on sympathetic nerve responses to hypoxia in normal humans. J Appl Physiol 1989;67:2095-100.
135. Leuenberger U, Jacob E, Sweer L, Waravdekar N, Zwillich C, Sinoway L. Surges of muscle sympathetic nerve activity during obstructive apnea are linked to hypoxemia. J Appl Physiol 1995;79:581-8.
136. Babior BM. Phagocytes and oxidative stress. Am J Med 2000;109:33-44.
137. Lavie L. Obstructive sleep apnoea syndrome - an oxidative stress disorder. Sleep Med Rev 2003;7:35-51.
138. Horner RL, Brooks D, Kozar LF, Tse S, Phillipson EA. Immediate effects of arousal from sleep on cardiac autonomic outfow in the absence of breathing in dogs. J Appl Physiol 1995;79:151-62.
139. Blasi A, Jo J, Valladares E, Morgan BJ, Skatrud JB, Khoo MC. Cardiovascular variability after arousal from sleep: time-varying spectral analysis. J Appl Physiol 2003;95:1394-404.
140. Blasi A, Jo JA, Valladares E, Juarez R, Baydur A, Khoo MC. Autonomic cardiovascular control following transient arousal from sleep: a time-varying closed-loop model. IEEE Trans Biomed Eng 2006;53:74-82.
141. Catcheside PG, Chiong SC, Mercer J, Saunders NA, McEvoy RD. Noninvasive cardiovascular markers of acoustically induced arousal from non-rapid-eye- movement sleep. Sleep 2002;25:797-804.
142. Nalivaiko E, Catcheside PG, Adams A, Jordan AS, Eckert DJ, McEvoy RD. Cardiac changes during arousals from non-REM sleep in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 2007;292:R1320-7.
143. Ekstedt M, Akerstedt T, Soderstrom M. Microarousals during sleep are associated with increased levels of lipids, cortisol, and blood pressure. Psychosom Med 2004;66:925-31.
144. Bonnet MH, Berry RB, Arand DL. Metabolism during normal, fragmented, and recovery sleep. J Appl Physiol 1991;71:1112-8.
145. Bonnet MH. Effect of sleep disruption on sleep, performance, and mood. Sleep 1985;8:11-9.
146. Ayas NT, White DP, Al-Delaimy WK, et al. A prospective study of self-reported sleep duration and incident diabetes in women. Diabetes Care 2003;26:380-4.
147. Andretic R, Shaw PJ. Essentials of sleep recordings in Drosophila: moving beyond sleep time. Methods Enzymol 2005;393:759-72.
148. Gangwisch JE, Heymsfeld SB, Boden-Albala B, et al. Short sleep duration as a risk factor for hypertension: analyses of the frst National Health and Nutrition Examination Survey. Hypertension 2006;47:833-9.
149. Yu Y, Lu BS, Wang B, et al. Short sleep duration and adiposity in Chinese adolescents. Sleep 2007;30:1688-97.
150. Spiegel K, Knutson K, Leproult R, Tasali E, Van Cauter E. Sleep loss: a novel risk factor for insulin resistance and Type 2 diabetes. J Appl Physiol 2005;99:2008-19.
151. Dinges DF, Pack F, Williams K, et al. Cumulative sleepiness, mood disturbance, and psychomotor vigilance performance decrements during a week of sleep restricted to 4-5 hours per night. Sleep 1997;20:267-7.
152. Van Dongen HP, Maislin G, Mullington JM, Dinges DF. The cumulative cost of additional wakefulness: dose-response effects on neurobehavioral functions and sleep physiology from chronic sleep restriction and total sleep deprivation. Sleep 2003;26:117-26.
153. Haack M, Mullington JM. Sustained sleep restriction reduces emotional and physical well-being. Pain 2005;119:56-64.
154. Casement MD, Broussard JL, Mullington JM, Press DZ. The contribution of sleep to improvements in working memory scanning speed: a study of prolonged sleep restriction. Biol Psychol 2006;72:208-12.
155. Meier-Ewert HK, Ridker PM, Rifai N, et al. Effect of sleep loss on C-reactive protein, an infammatory marker of cardiovascular risk. J Am Coll Cardiol 2004;43:678-83.
156. Vgontzas AN, Zoumakis E, Bixler EO, et al. Adverse effects of modest sleep restriction on sleepiness, performance, and infammatory cytokines. J Clin Endocrinol Metab 2004;89:2119-26.
157. Irwin MR, Wang M, Campomayor CO, Collado-Hidalgo A, Cole S. Sleep deprivation and activation of morning levels of cellular and genomic markers of infammation. Arch Intern Med 2006;166:1756-62.
158. Jain V. Clinical perspective of obstructive sleep apnea-induced cardiovascular complications. Antioxid Redox Signal 2007;9:701- 10.
159. Umlauf MG, Chasens ER. Sleep disordered breathing and nocturnal polyuria: nocturia and enuresis. Sleep Med Rev 2003;7:403- 11.
160. Lew RA, Baertschi AJ. Mechanisms of hypoxia-induced atrial natriuretic factor release from rat hearts. Am J Physiol 1989;257:H147-56.
161. Lin CC, Tsan KW, Lin C Y. Plasma levels of atrial natriuretic factor in moderate to severe obstructive sleep apnea syndrome. Sleep 1993;16:37-9.
162. Umlauf MG, Chasens ER, Greevy RA, Arnold J, Burgio KL, Pillion DJ. Obstructive sleep apnea, nocturia and polyuria in older adults. Sleep 2004;27:139-44.
163. Krieger J, Follenius M, Sforza E, Brandenberger G, Peter JD. Effects of treatment with nasal continuous positive airway pressure on atrial natriuretic peptide and arginine vasopressin release during sleep in patients with obstructive sleep apnoea. Clin Sci (Lond) 1991;80:443-9.
164. Krieger J, Laks L, Wilcox I, et al. Atrial natriuretic peptide release during sleep in patients with obstructive sleep apnoea before and during treatment with nasal continuous positive airway pressure. Clin Sci (Lond) 1989;77:407-11.
165. Kita H, Ohi M, Chin K, et al. The nocturnal secretion of cardiac natriuretic peptides during obstructive sleep apnoea and its response to therapy with nasal continuous positive airway pressure. J Sleep Res 1998;7:199-207.
166. Yalkut D, Lee LY, Grider J, Jorgensen M, Jackson B, Ott C. Mechanism of atrial natriuretic peptide release with increased inspiratory resistance. J Lab Clin Med 1996;128:322-8.
167. Schafer H, Ehlenz K, Ewig S, et al. Atrial natriuretic peptide levels and pulmonary artery pressure awake, at exercise and asleep in obstructive sleep apnoea syndrome. J Sleep Res 1999;8:205-10.
168. Patwardhan AA, Larson MG, Levy D, et al. Obstructive sleep apnea and plasma natriuretic peptide levels in a community-based sample. Sleep 2006;29:1301-6.
169. Gjorup PH, Sadauskiene L, Wessels J, Nyvad O, Strunge B, Pedersen EB. Increased nocturnal sodium excretion in obstructive sleep apnoea. Relation to nocturnal change in diastolic blood pressure. Scand J Clin Lab Invest 2008;68:11-21.
170. Kimura K, Yamaguchi Y, Horii M, et al. ANP is cleared much faster than BNP in patients with congestive heart failure. Eur J Clin Pharmacol 2007;63:699-702.
171. Yandle TG, Richards AM, Nicholls MG, Cuneo R, Espiner EA, Livesey JH. Metabolic clearance rate and plasma half life of alphahuman atrial natriuretic peptide in man. Life Sci 1986;38:1827-33.
172. Exar EN, Collop NA. The upper airway resistance syndrome. Chest 1999;115:1127-39.
173. Guilleminault C, Stoohs R, Shiomi T, Kushida C, Schnittger I. Upper airway resistance syndrome, nocturnal blood pressure monitoring, and borderline hypertension. Chest 1996;109:901-8.
174. Chen L, Scharf SM. Comparative hemodynamic effects of periodic obstructive and simulated central apneas in sedated pigs. J Appl Physiol 1997;83:485-94.
175. White SG, Fletcher EC, Miller CC, 3rd. Acute systemic blood pressure elevation in obstructive and nonobstructive breath hold in primates. J Appl Physiol 1995;79:324-30.
176. Almendros I, Carreras A, Ramirez J, Montserrat JM, Navajas D, Farre R. Upper airway collapse and reopening induce infammation in a sleep apnoea model. Eur Respir J 2008;32:399-404.
177. Almendros I, Acerbi I, Puig F, Montserrat JM, Navajas D, Farre R. Upper-airway infammation triggered by vibration in a rat model of snoring. Sleep 2007;30:225-7.
178. Narkiewicz K, van de Borne PJ, Cooley RL, Dyken ME, Somers VK. Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation 1998;98:772-6.
179. Grassi G, Facchini A, Trevano FQ, et al. Obstructive sleep apneadependent and -independent adrenergic activation in obesity. Hypertension 2005;46:321-5.
180. Waradekar NV, Sinoway LI, Zwillich CW, Leuenberger UA. Infuence of treatment on muscle sympathetic nerve activity in sleep apnea. Am J Respir Crit Care Med 1996;153:1333-8.
181. Narkiewicz K, Kato M, Phillips BG, Pesek CA, Davison DE, Somers VK. Nocturnal continuous positive airway pressure decreases daytime sympathetic traffc in obstructive sleep apnea. Circulation 1999;100:2332-5.
182. Donadio V, Liguori R, Vetrugno R, et al. Daytime sympathetic hyperactivity in OSAS is related to excessive daytime sleepiness. J Sleep Res 2007;16:327-32.
183. Goldstein DS, Eisenhofer G, Kopin IJ. Sources and signifcance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther 2003;305:800-11.
184. Fletcher EC, Miller J, Schaaf JW, Fletcher JG. Urinary catecholamines before and after tracheostomy in patients with obstructive sleep apnea and hypertension. Sleep 1987;10:35-44.
185. McArdle N, Hillman D, Beilin L, Watts G. Metabolic risk factors for vascular disease in obstructive sleep apnea: a matched controlled study. Am J Respir Crit Care Med 2007;175:190-5.
186. Drager LF, Bortolotto LA, Figueiredo AC, Krieger EM, Lorenzi GF. Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 2007;176:706-12.
187. Heitmann J, Ehlenz K, Penzel T, et al. Sympathetic activity is reduced by nCPAP in hypertensive obstructive sleep apnoea patients. Eur Respir J 2004;23:255-62.
188. Mansfeld DR, Gollogly NC, Kaye DM, Richardson M, Bergin P, Naughton MT. Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure. Am J Respir Crit Care Med 2004;169:361-6.
189. Ziegler MG, Mills PJ, Loredo JS, Ancoli-Israel S, Dimsdale JE. Effect of continuous positive airway pressure and placebo treatment on sympathetic nervous activity in patients with obstructive sleep apnea. Chest 2001;120:887-93.
190. Hedner J, Darpo B, Ejnell H, Carlson J, Caidahl K. Reduction in sympathetic activity after long-term CPAP treatment in sleep apnoea: cardiovascular implications. Eur Respir J 1995;8:222-9.
191. Minemura H, Akashiba T, Yamamoto H, Akahoshi T, Kosaka N, Horie T. Acute effects of nasal continuous positive airway pressure on 24-hour blood pressure and catecholamines in patients with obstructive sleep apnea. Intern Med 1998;37:1009-13.
192. Sukegawa M, Noda A, Sugiura T, et al. Assessment of continuous positive airway pressure treatment in obstructive sleep apnea syndrome using 24-hour urinary catecholamines. Clin Cardiol 2005;28:519-22.
193. Marrone O, Riccobono L, Salvaggio A, Mirabella A, Bonanno A, Bonsignore MR. Catecholamines and blood pressure in obstructive sleep apnea syndrome. Chest 1993;103:722-7.
194. Grunstein RR, Stewart DA, Lloyd H, Akinci M, Cheng N, Sullivan CE. Acute withdrawal of nasal CPAP in obstructive sleep apnea does not cause a rise in stress hormones. Sleep 1996;19:774-82.
195. Phillips CL, Yang Q, Williams A, et al. The effect of short-term withdrawal from continuous positive airway pressure therapy on sympathetic activity and markers of vascular infammation in subjects with obstructive sleep apnoea. J Sleep Res 2007;16:217-25.
196. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 1995;96:1897-904.
197. Wieber SJ. The cardiac consequences of the obstructive sleep apnea-hypopnea syndrome. Mt Sinai J Med 2005;72:10-2.
198. Marcus C, Ehren H, Bolme P, Arner P. Regulation of lipolysis during the neonatal period. Importance of thyrotropin. J Clin Invest 1988;82:1793-7.
199. Hucking K, Hamilton-Wessler M, Ellmerer M, Bergman RN. Burst-like control of lipolysis by the sympathetic nervous system in vivo. J Clin Invest 2003;111:257-64.
200. Coppack SW, Jensen MD, Miles JM. In vivo regulation of lipolysis in humans. J Lipid Res 1994;35:177-93.
201. Nguyen MT, Favelyukis S, Nguyen AK, et al. A subpopulation of macrophages infltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK- dependent pathways. J Biol Chem 2007;282:35279-92.
202. Nguyen MT, Satoh H, Favelyukis S, et al. JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem 2005;280:35361-71.
203. Kim SP, Catalano KJ, Hsu IR, Chiu JD, Richey JM, Bergman RN. Nocturnal free fatty acids are uniquely elevated in the longitudinal development of diet-induced insulin resistance and hyperinsulinemia. Am J Physiol Endocrinol Metab 2007;292:E1590-8.
204. Bergman RN, Ader M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 2000;11:351-6.
205. Makino S, Handa H, Suzukawa K, et al. Obstructive sleep apnoea syndrome, plasma adiponectin levels, and insulin resistance. Clin Endocrinol (Oxf) 2006;64:12-9.
206. Barcelo A, Miralles C, Barbe F, Vila M, Pons S, Agusti AG. Abnormal lipid peroxidation in patients with sleep apnoea. Eur Respir J 2000;16:644-7.
207. Lavie L, Vishnevsky A, Lavie P. Evidence for lipid peroxidation in obstructive sleep apnea. Sleep 2004;27:123-8.
208. Yamauchi M, Nakano H, Maekawa J, et al. Oxidative stress in obstructive sleep apnea. Chest 2005;127:1674-9.
209. Minoguchi K, Yokoe T, Tanaka A, et al. Association between lipid peroxidation and infammation in obstructive sleep apnoea. Eur Respir J 2006;28:378-85.
210. Morrow JD, Roberts LJ. The isoprostanes: their role as an index of oxidant stress status in human pulmonary disease. Am J Respir Crit Care Med 2002;166:S25-30.
211. Halliwell B, Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol 2004;142:231-55.
212. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem 2006;52:601-23.
213. Kadiiska MB, Gladen BC, Baird DD, et al. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med 2005;38:698-710.
214. Svatikova A, Wolk R, Lerman LO, et al. Oxidative stress in obstructive sleep apnoea. Eur Heart J 2005;26:2435-9.
215. Ozturk L, Mansour B, Yuksel M, Yalcin AS, Celikoglu F, Gokhan N. Lipid peroxidation and osmotic fragility of red blood cells in sleep-apnea patients. Clin Chim Acta 2003;332:83-8.
216. Alzoghaibi MA, Bahammam AS. Lipid peroxides, superoxide dismutase and circulating IL-8 and GCP-2 in patients with severe obstructive sleep apnea: a pilot study. Sleep Breath 2005;9:119-26.
217. Yan W, Byrd GD, Ogden MW. Quantitation of isoprostane isomers in human urine from smokers and nonsmokers by LC-MS/ MS. J Lipid Res 2007;48:1607-17.
218. Basu S. Metabolism of 8-iso-prostaglandin F2alpha. FEBS Lett 1998;428:32-6.
219. Griffths HR, Moller L, Bartosz G, et al. Biomarkers. Mol Aspects Med 2002;23:101-208.
220. Morrow JD, Zackert WE, Yang JP, et al. Quantifcation of the major urinary metabolite of 15-F2t-isoprostane (8-iso-PGF2alpha) by a stable isotope dilution mass spectrometric assay. Anal Biochem 1999;269:326-31.
221. Liu H, Liu J, Xiong S, Shen G, Zhang Z, Xu Y. The change of interleukin-6 and tumor necrosis factor in patients with obstructive sleep apnea syndrome. J Tongji Med Univ 2000;20:200-2.
222. Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al. Elevated C- reactive protein in patients with obstructive sleep apnea. Circulation 2002;105:2462-4.
223. Yokoe T, Minoguchi K, Matsuo H, et al. Elevated levels of C- reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003;107:1129-34.
224. Minoguchi K, Tazaki T, Yokoe T, et al. Elevated production of tumor necrosis factor-alpha by monocytes in patients with obstructive sleep apnea syndrome. Chest 2004;126:1473-9.
225. Minoguchi K, Yokoe T, Tazaki T, et al. Increased carotid intimamedia thickness and serum infammatory markers in obstructive sleep apnea. Am J Respir Crit Care Med 2005;172:625-30.
226. Kobayashi K, Nishimura Y, Shimada T, et al. Effect of continuous positive airway pressure on soluble CD40 ligand in patients with obstructive sleep apnea syndrome. Chest 2006;129:632-7.
227. Bravo Mde L, Serpero LD, Barcelo A, Barbe F, Agusti A, Gozal D. Infammatory proteins in patients with obstructive sleep apnea with and without daytime sleepiness. Sleep Breath 2007;11:177-85.
228. Guilleminault C, Kirisoglu C, Ohayon MM. C-reactive protein and sleep-disordered breathing. Sleep 2004;27:1507-11.
229. Sharma SK, Mishra HK, Sharma H, et al. Obesity, and not obstructive sleep apnea, is responsible for increased serum hs-CRP levels in patients with sleep-disordered breathing in Delhi. Sleep Med 2008;9:149-56.
230. Roytblat L, Rachinsky M, Fisher A, et al. Raised interleukin-6 levels in obese patients. Obes Res 2000;8:673-5.
231. Mehra R, Storfer-Isser A, Kirchner HL, et al. Soluble interleukin 6 receptor: A novel marker of moderate to severe sleep-related breathing disorder. Arch Intern Med 2006;166:1725-31.
232. Vgontzas AN, Papanicolaou DA, Bixler EO, et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000;85:1151-8.
233. Hayashi M, Fujimoto K, Urushibata K, Takamizawa A, Kinoshita O, Kubo K. Hypoxia-sensitive molecules may modulate the development of atherosclerosis in sleep apnoea syndrome. Respirology 2006;11:24-31.
234. Paulsen FP, Steven P, Tsokos M, et al. Upper airway epithelial structural changes in obstructive sleep-disordered breathing. Am J Respir Crit Care Med 2002;166:501-9.
235. Boyd JH, Petrof BJ, Hamid Q, Fraser R, Kimoff RJ. Upper airway muscle infammation and denervation changes in obstructive sleep apnea. Am J Respir Crit Care Med 2004;170:541-6.
236. Sabato R, Guido P, Salerno FG, Resta O, Spanevello A, Barbaro MP. Airway infammation in patients affected by obstructive sleep apnea. Monaldi Arch Chest Dis 2006;65:102-5.
237. Exley AR, Cohen J. Optimal collection of blood samples for the measurement of tumor necrosis factor alpha. Cytokine 1990;2:353-6.
238. Flower L, Ahuja RH, Humphries SE, Mohamed-Ali V. Effects of sample handling on the stability of interleukin 6, tumour necrosis factor-alpha and leptin. Cytokine 2000;12:1712-6.
239. Seiler W, Muller H, Hiemke C. Interleukin-6 in plasma collected with an indwelling cannula refects local, not systemic, concentrations. Clin Chem 1994;40:1778-9.
240. Gudmundsson A, Ershler WB, Goodman B, Lent SJ, Barczi S, Carnes M. Serum concentrations of interleukin-6 are increased when sampled through an indwelling venous catheter. Clin Chem 1997;43:2199-201.
241. Haack M, Kraus T, Schuld A, Dalal M, Koethe D, Pollmacher T. Diurnal variations of interleukin-6 plasma levels are confounded by blood drawing procedures. Psychoneuroendocrinology 2002;27:921-31.
242. Haack M, Reichenberg A, Kraus T, Schuld A, Yirmiya R, Pollmacher T. Effects of an intravenous catheter on the local production of cytokines and soluble cytokine receptors in healthy men. Cytokine 2000;12:694-8.
243. Bekri S, Gual P, Anty R, et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 2006;131:788-96.
244. Bae SK, Kim SR, Kim JG, et al. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Lett 2006;580:4105-13.
245. Segawa K, Fukuhara A, Hosogai N, et al. Visfatin in adipocytes is upregulated by hypoxia through HIF1alpha-dependent mechanism. Biochem Biophys Res Commun 2006;349:875-82.
246. Bo S, Ciccone G, Durazzo M, et al. Effcacy of antioxidant treatment in reducing resistin serum levels: a randomized study. PLoS Clin Trials 2007;2:e17.
247. Kamigaki M, Sakaue S, Tsujino I, et al. Oxidative stress provokes atherogenic changes in adipokine gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2006;339:624-32.
248. Soares AF, Guichardant M, Cozzone D, et al. Effects of oxidative stress on adiponectin secretion and lactate production in 3T3-L1 adipocytes. Free Radic Biol Med 2005;38:882-9.
249. Sarraf P, Frederich RC, Turner EM, et al. Multiple cytokines and acute infammation raise mouse leptin levels: potential role in infammatory anorexia. J Exp Med 1997;185:171-5.
250. Grunfeld C, Zhao C, Fuller J, et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest 1996;97:2152-7.
251. Faggioni R, Fantuzzi G, Fuller J, Dinarello CA, Feingold KR, Grunfeld C. IL-1 beta mediates leptin induction during infammation. Am J Physiol 1998;274:R204-8.
252. Hector J, Schwarzloh B, Goehring J, et al. TNF-alpha alters visfatin and adiponectin levels in human fat. Horm Metab Res 2007;39:250-5.
253. Fasshauer M, Kralisch S, Klier M, et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2003;301:1045-50.
254. Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. An infammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004;1:e45.
255. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinfammatory properties. J Immunol 2005;174:5789-95.
256. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Tumor necrosis factor alpha is a negative regulator of resistin gene expression and secretion in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2001;288:1027-31.
257. Nowell MA, Richards PJ, Fielding CA, et al. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 2006;54:2084-95.
258. Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003;285:E527-33.
259. Shojima N, Sakoda H, Ogihara T, et al. Humoral regulation of resistin expression in 3T3-L1 and mouse adipose cells. Diabetes 2002;51:1737-44.
260. Roebuck KA, Finnegan A. Regulation of intercellular adhesion molecule-1 (CD54) gene expression. J Leukoc Biol 1999;66:876-88.
261. Roebuck KA. Oxidant stress regulation of IL-8 and ICAM-1 gene expression: differential activation and binding of the transcription factors AP-1 and NF-kappaB. Int J Mol Med 1999;4:223-30.
262. Lago F, Dieguez C, Gomez-Reino J, Gualillo O. The emerging role of adipokines as mediators of infammation and immune responses. Cytokine Growth Factor Rev 2007;18:313-25.
263. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin--the classical, resistin--the controversical, adiponectin--the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005;19:525-46.
264. Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and infammation. J Clin Invest 2002;110:1037-44.
265. Hashimoto T, Kihara M, Imai N, et al. Requirement of apelinapelin receptor system for oxidative stress-linked atherosclerosis. Am J Pathol 2007;171:1705-12.
266. Kim SR, Bae YH, Bae SK, et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta 2008;1783:886- 95.
267. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of infammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-6.
268. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of infammation, is a type II acute-phase protein. Blood 2003;101:2461-3.
269. Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 2005;102:10610-5.
270. Daviaud D, Boucher J, Gesta S, et al. TNFalpha up-regulates apelin expression in human and mouse adipose tissue. FASEB J 2006;20:1528-30.
271. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinfammatory and immunomodulating properties. J Immunol 2007;178:1748-58.
272. Wen Y, Wang HW, Wu J, Lu HL, Hu XF, Cianfone K. Effects of fatty acid regulation on visfatin gene expression in adipocytes. Chin Med J (Engl) 2006;119:1701-8.
273. Yildiz BO, Suchard MA, Wong ML, McCann SM, Licinio J. Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proc Natl Acad Sci U S A 2004;101:10434-9.
274. Shea SA, Hilton MF, Orlova C, Ayers RT, Mantzoros CS. Independent circadian and sleep/wake regulation of adipokines and glucose in humans. J Clin Endocrinol Metab 2005;90:2537-44.
275. Farooqi IS, Bullmore E, Keogh J, Gillard J, O'Rahilly S, Fletcher PC. Leptin regulates striatal regions and human eating behavior. Science 2007;317:1355.
276. Alam I, Lewis K, Stephens JW, Baxter JN. Obesity, metabolic syndrome and sleep apnoea: all pro-infammatory states. Obes Rev 2006;8:119-27.
277. Otero M, Lago R, Gomez R, et al. Towards a pro-infammatory and immunomodulatory emerging role of leptin. Rheumatology (Oxford) 2006;45:944-50.
278. Sanna V, Di Giacomo A, La Cava A, et al. Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. J Clin Invest 2003;111:241-50.
279. Farooqi IS, Matarese G, Lord GM, et al. Benefcial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/ metabolic dysfunction of human congenital leptin defciency. J Clin Invest 2002;110:1093-103.
280. Zhao Y, Sun R, You L, Gao C, Tian Z. Expression of leptin receptors and response to leptin stimulation of human natural killer cell lines. Biochem Biophys Res Commun 2003;300:247-52.
281. Raso GM, Pacilio M, Esposito E, Coppola A, Di Carlo R, Meli R. Leptin potentiates IFN-gamma-induced expression of nitric oxide synthase and cyclo-oxygenase-2 in murine macrophage J774A.1. Br J Pharmacol 2002;137:799-804.
282. Zarkesh-Esfahani H, Pockley G, Metcalfe RA, et al. High-dose leptin activates human leukocytes via receptor expression on monocytes. J Immunol 2001;167:4593-9.
283. Bravo PE, Morse S, Borne DM, Aguilar EA, Reisin E. Leptin and hypertension in obesity. Vasc Health Risk Manag 2006;2:163-9.
284. Bullo M, Garcia-Lorda P, Megias I, Salas-Salvado J. Systemic infammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res 2003;11:525-31.
285. Bullo M, Garcia-Lorda P, Salas-Salvado J. Plasma soluble tumor necrosis factor alpha receptors and leptin levels in normal-weight and obese women: effect of adiposity and diabetes. Eur J Endocrinol 2002;146:325-31.
286. Ciccone M, Vettor R, Pannacciulli N, et al. Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord 2001;25:805-10.
287. Schafer K, Halle M, Goeschen C, et al. Leptin promotes vascular remodeling and neointimal growth in mice. Arterioscler Thromb Vasc Biol 2004;24:112-7.
288. Paolisso G, Tagliamonte MR, Galderisi M, et al. Plasma leptin level is associated with myocardial wall thickness in hypertensive insulin-resistant men. Hypertension 1999;34:1047-52.
289. de Courten M, Zimmet P, Hodge A, et al. Hyperleptinaemia: the missing link in the, metabolic syndrome? Diabet Med 1997;14:200-8.
290. Wabitsch M, Jensen PB, Blum WF, et al. Insulin and cortisol promote leptin production in cultured human fat cells. Diabetes 1996;45:1435-8.
291. Russell CD, Petersen RN, Rao SP, et al. Leptin expression in adipose tissue from obese humans: depot-specifc regulation by insulin and dexamethasone. Am J Physiol 1998;275:E507-15.
292. Wang J, Obici S, Morgan K, Barzilai N, Feng Z, Rossetti L. Overfeeding rapidly induces leptin and insulin resistance. Diabetes 2001;50:2786-91.
293. Muller G, Ertl J, Gerl M, Preibisch G. Leptin impairs metabolic actions of insulin in isolated rat adipocytes. J Biol Chem 1997;272:10585-93.
294. Chinookoswong N, Wang JL, Shi ZQ. Leptin restores euglycemia and normalizes glucose turnover in insulin-defcient diabetes in the rat. Diabetes 1999;48:1487-92.
295. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999;401:73-6.
296. Phillips BG, Kato M, Narkiewicz K, Choe I, Somers VK. Increases in leptin levels, sympathetic drive, and weight gain in obstructive sleep apnea. Am J Physiol Heart Circ Physiol 2000;279:H234-7.
297. Tatsumi K, Kasahara Y, Kurosu K, Tanabe N, Takiguchi Y, Kuriyama T. Sleep oxygen desaturation and circulating leptin in obstructive sleep apnea-hypopnea syndrome. Chest 2005;127:716-21.
298. Barcelo A, Barbe F, Llompart E, et al. Neuropeptide Y and leptin in patients with obstructive sleep apnea syndrome: role of obesity. Am J Respir Crit Care Med 2005;171:183-7.
299. Chin K, Shimizu K, Nakamura T, et al. Changes in intra-abdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy. Circulation 1999;100:706-12.
300. Shimizu K, Chin K, Nakamura T, et al. Plasma leptin levels and cardiac sympathetic function in patients with obstructive sleep apnoea-hypopnoea syndrome. Thorax 2002;57:429-34.
301. Harsch IA, Konturek PC, Koebnick C, et al. Leptin and ghrelin levels in patients with obstructive sleep apnoea: effect of CPAP treatment. Eur Respir J 2003;22:251-7.
302. Trenell MI, Ward JA, Yee BJ, et al. Infuence of constant positive airway pressure therapy on lipid storage, muscle metabolism and insulin action in obese patients with severe obstructive sleep apnoea syndrome. Diabetes Obes Metab 2007;9:679-87.
303. Harsch IA, Schahin SP, Bruckner K, et al. The effect of continuous positive airway pressure treatment on insulin sensitivity in patients with obstructive sleep apnoea syndrome and type 2 diabetes. Respiration 2004;71:252-9.
304. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specifc gene dysregulated in obesity. J Biol Chem 1996;271:10697-703.
305. Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purifed from human plasma. J Biochem 1996;120:803-12.
306. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 2001;98:2005-10.
307. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947-53.
308. Masserini B, Morpurgo PS, Donadio F, et al. Reduced levels of adiponectin in sleep apnea syndrome. J Endocrinol Invest 2006;29:700-5.
309. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specifc protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-9.
310. Shin MJ, Lee JH, Jang Y, et al. Insulin resistance, adipokines, and oxidative stress in nondiabetic, hypercholesterolemic patients: leptin as an 8-epi-prostaglandin F2alpha determinant. Metabolism 2006;55:918-22.
311. Tan KC, Xu A, Chow WS, et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab 2004;89:765-9.
312. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004;291:1730-7.
313. Masaki T, Chiba S, Tatsukawa H, et al. Adiponectin protects LPS- induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 2004;40:177-84.
314. Ajuwon KM, Spurlock ME. Adiponectin inhibits LPS-induced NF-kappaB activation and IL-6 production and increases PPAR- gamma2 expression in adipocytes. Am J Physiol Regul Integr Comp Physiol 2005;288:R1220-5.
315. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000;102:1296-301.
316. Wulster-Radcliffe MC, Ajuwon KM, Wang J, Christian JA, Spurlock ME. Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 2004;316:924-9.
317. Zhang XL, Yin KS, Wang H, Su S. Serum adiponectin levels in adult male patients with obstructive sleep apnea hypopnea syndrome. Respiration 2006;73:73-7.
318. Nakagawa Y, Kishida K, Kihara S, et al. Nocturnal reduction in circulating adiponectin concentrations related to hypoxic stress in severe obstructive sleep apnea-hypopnea syndrome. Am J Physiol Endocrinol Metab 2008;294:E778-84.
319. Wolk R, Svatikova A, Nelson CA, et al. Plasma levels of adiponectin, a novel adipocyte-derived hormone, in sleep apnea. Obes Res 2005;13:186-90.
320. Zhang XL, Yin KS, Li C, Jia EZ, Li YQ, Gao ZF. Effect of continuous positive airway pressure treatment on serum adiponectin level and mean arterial pressure in male patients with obstructive sleep apnea syndrome. Chin Med J (Engl) 2007;120:1477-81.
321. Harsch IA, Wallaschofski H, Koebnick C, et al. Adiponectin in patients with obstructive sleep apnea syndrome: course and physiological relevance. Respiration 2004;71:580-6.
322. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-12.
323. Patel L, Buckels AC, Kinghorn IJ, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003;300:472-6.
324. Fain JN, Cheema PS, Bahouth SW, Lloyd Hiler M. Resistin release by human adipose tissue explants in primary culture. Biochem Biophys Res Commun 2003;300:674-8.
325. Yura S, Sagawa N, Itoh H, et al. Resistin is expressed in the human placenta. J Clin Endocrinol Metab 2003;88:1394-7.
326. Minn AH, Patterson NB, Pack S, et al. Resistin is expressed in pancreatic islets. Biochem Biophys Res Commun 2003;310:641-5.
327. Anderson PD, Mehta NN, Wolfe ML, et al. Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab 2007;92:2272-9.
328. Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 2003;111:225-30.
329. Moon B, Kwan JJ, Duddy N, Sweeney G, Begum N. Resistin inhibits glucose uptake in L6 cells independently of changes in insulin signaling and GLUT4 translocation. Am J Physiol Endocrinol Metab 2003;285:E106-15.
330. Palanivel R, Maida A, Liu Y, Sweeney G. Regulation of insulin signalling, glucose uptake and metabolism in rat skeletal muscle cells upon prolonged exposure to resistin. Diabetologia 2006;49:183-90.
331. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an infammatory marker of atherosclerosis in humans. Circulation 2005;111:932-9.
332. Savage DB, Sewter CP, Klenk ES, et al. Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001;50:2199-202.
333. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, infammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004;27:2450-7.
334. Senolt L, Housa D, Vernerova Z, et al. Resistin in rheumatoid arthritis synovial tissue, synovial fuid and serum. Ann Rheum Dis 2007;66:458-63.
335. Rajala MW, Lin Y, Ranalletta M, et al. Cell type-specifc expression and coregulation of murine resistin and resistin-like molecule-alpha in adipose tissue. Mol Endocrinol 2002;16:1920-30.
336. Burnett MS, Lee CW, Kinnaird TD, et al. The potential role of resistin in atherogenesis. Atherosclerosis 2005;182:241-8.
337. Verma S, Li SH, Wang CH, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003;108:736-40.
338. Harsch IA, Koebnick C, Wallaschofski H, et al. Resistin levels in patients with obstructive sleep apnoea syndrome--the link to subclinical infammation? Med Sci Monit 2004;10:CR510-5.
339. Yamamoto Y, Fujiuchi S, Hiramatsu M, et al. Resistin is closely related to systemic infammation in obstructive sleep apnea. Respiration 2008;76:377-85.
340. Tauman R, Serpero LD, Capdevila OS, et al. Adipokines in children with sleep disordered breathing. Sleep 2007;30:443-9.
341. Kanbay A, Hasanoglu HC. A new prognostic marker for obstructive sleep apnea: hepcidin. Med Hypotheses 2007;69:1381-2.
342. Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:2292-301.
343. Sawa Y, Sugimoto Y, Ueki T, et al. Effects of TNF-alpha on leukocyte adhesion molecule expressions in cultured human lymphatic endothelium. J Histochem Cytochem 2007;55:721-33.
344. Sawa Y, Ueki T, Hata M, et al. LPS-induced IL-6, IL-8, VCAM-1, and ICAM-1 expression in human lymphatic endothelium. J Histochem Cytochem 2008;56:97-109.
345. Kalogeris TJ, Kevil CG, Laroux FS, Coe LL, Phifer TJ, Alexander JS. Differential monocyte adhesion and adhesion molecule expression in venous and arterial endothelial cells. Am J Physiol 1999;276:L9-L19.
346. Elangbam CS, Qualls CW, Jr., Dahlgren RR. Cell adhesion molecules--update. Vet Pathol 1997;34:61-73.
347. Htoo AK, Greenberg H, Tongia S, et al. Activation of nuclear factor kappaB in obstructive sleep apnea: a pathway leading to systemic infammation. Sleep Breath 2006;10:43-50.
348. Ohga E, Nagase T, Tomita T, et al. Increased levels of circulating ICAM-1, VCAM-1, and L-selectin in obstructive sleep apnea syndrome. J Appl Physiol 1999;87:10-4.
349. Ohga E, Tomita T, Wada H, Yamamoto H, Nagase T, Ouchi Y. Effects of obstructive sleep apnea on circulating ICAM-1, IL-8, and MCP-1. J Appl Physiol 2003;94:179-84.
350. Ursavas A, Karadag M, Rodoplu E, Yilmaztepe A, Oral HB, Gozu RO. Circulating ICAM-1 and VCAM-1 levels in patients with obstructive sleep apnea syndrome. Respiration 2007;74:525-32.
351. Chin K, Nakamura T, Shimizu K, Mishima M, Miyasaka M, Ohi M. Effects of nasal continuous positive airway pressure on soluble cell adhesion molecules in patients with obstructive sleep apnea syndrome. Am J Med 2000;109:562-7.
352. Schroder M, Kaufman RJ. ER stress and the unfolded protein response. Mutat Res 2005;569:29-63.
353. Magagnin MG, Sergeant K, van den Beucken T, et al. Proteomic analysis of gene expression following hypoxia and reoxygenation reveals proteins involved in the recovery from endoplasmic reticulum and oxidative stress. Radiother Oncol 2007;83:340-5.
354. Thuerauf DJ, Marcinko M, Gude N, Rubio M, Sussman MA, Glembotski CC. Activation of the unfolded protein response in infarcted mouse heart and hypoxic cultured cardiac myocytes. Circ Res 2006;99:275-82.
355. Feng B, Yao PM, Li Y, et al. The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat Cell Biol 2003;5:781-92.
356. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004;306:457-61.
357. Boden G, Duan X, Homko C, et al. Increase in Endoplasmic Reticulum (ER) Stress Related Proteins and Genes in Adipose Tissue of Obese, Insulin Resistant Individuals. Diabetes 2008;57:2438-44.
358. Hotamisligil GS. Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in infammation and origin of obesity and diabetes. Diabetes 2005;54 Suppl 2:S73-8.
359. Boden G, Duan X, Homko C, et al. Increase in endoplasmic reticulum stress-related proteins and genes in adipose tissue of obese, insulin-resistant individuals. Diabetes 2008;57:2438-44.
360. Li J, Lee AS. Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med 2006;6:45-54.
361. Zhu Y, Fenik P, Zhan G, Sanfllipo-Cohn B, Naidoo N, Veasey SC. Eif-2a protects brainstem motoneurons in a murine model of sleep apnea. J Neurosci 2008;28:2168-78.
362. Naidoo N, Casiano V, Cater J, Zimmerman J, Pack AI. A role for the molecular chaperone protein BiP/GRP78 in Drosophila sleep homeostasis. Sleep 2007;30:557-65.
363. Naidoo N, Giang W, Galante RJ, Pack AI. Sleep deprivation induces the unfolded protein response in mouse cerebral cortex. J Neurochem 2005;92:1150-7.
364. Cirelli C, Tononi G. Gene expression in the brain across the sleepwaking cycle. Brain Res 2000;885:303-21.
365. Jones S, Pfster-Genskow M, Benca RM, Cirelli C. Molecular correlates of sleep and wakefulness in the brain of the white-crowned sparrow. J Neurochem 2008;105:46-62.
366. Shaw PJ, Cirelli C, Greenspan RJ, Tononi G. Correlates of sleep and waking in Drosophila melanogaster. Science 2000;287:1834-7.
367. Terao A, Wisor JP, Peyron C, et al. Gene expression in the rat brain during sleep deprivation and recovery sleep: an Affymetrix GeneChip study. Neuroscience 2006;137:593-605.
368. Shinohara E, Kihara S, Yamashita S, et al. Visceral fat accumulation as an important risk factor for obstructive sleep apnoea syndrome in obese subjects. J Intern Med 1997;241:11-8.
369. Grunstein R, Wilcox I, Yang TS, Gould Y, Hedner J. Snoring and sleep apnoea in men: association with central obesity and hypertension. Int J Obes Relat Metab Disord 1993;17:533-40.
370. Young T, Skatrud J, Peppard PE. Risk factors for obstructive sleep apnea in adults. JAMA 2004;291:2013-6.
371. Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA 2000;284:3015-21.
372. Frey WC, Pilcher J. Obstructive sleep-related breathing disorders in patients evaluated for bariatric surgery. Obes Surg 2003;13:676-83.
373. Hoffstein V, Mateika S. Differences in abdominal and neck circumferences in patients with and without obstructive sleep apnoea. Eur Respir J 1992;5:377-81.
374. Millman RP, Carlisle CC, McGarvey ST, Eveloff SE, Levinson PD. Body fat distribution and sleep apnea severity in women. Chest 1995;107:362-6.
375. Catheline JM, Bihan H, Le Quang T, et al. Preoperative cardiac and pulmonary assessment in bariatric surgery. Obes Surg 2008;18:271-7.
376. Hallowell PT, Stellato TA, Schuster M, et al. Potentially lifethreatening sleep apnea is unrecognized without aggressive evaluation. Am J Surg 2007;193:364-7.
377. Lee YH, Johan A, Wong KK, Edwards N, Sullivan C. Prevalence and risk factors for obstructive sleep apnea in a multiethnic population of patients presenting for bariatric surgery in Singapore. Sleep Med 2008; Mar 31 [Epub ahead of print].
378. Daltro C, Gregorio PB, Alves E, et al. Prevalence and severity of sleep apnea in a group of morbidly obese patients. Obes Surg 2007;17:809-14.
379. Rader DJ. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med 2007;120:S12-8.
380. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-9.
381. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006;444:875-80.
382. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001;86:713-8.
383. Harsch IA, Schahin SP, Radespiel-Troger M, et al. Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2004;169:156-62.
384. Brooks B, Cistulli PA, Borkman M, et al. Obstructive sleep apnea in obese noninsulin-dependent diabetic patients: effect of continuous positive airway pressure treatment on insulin responsiveness. J Clin Endocrinol Metab 1994;79:1681-5.
385. Bazzano LA, Khan Z, Reynolds K, He J. Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. Hypertension 2007;50:417-23.
386. Haentjens P, Van Meerhaeghe A, Moscariello A, et al. The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome: evidence from a meta-analysis of placebo-controlled randomized trials. Arch Intern Med 2007;167:757-64.
387. Faccenda JF, Mackay TW, Boon NA, Douglas NJ. Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in the sleep apnea-hypopnea syndrome. Am J Respir Crit Care Med 2001;163:344-8.
388. Pepperell JC, Ramdassingh-Dow S, Crosthwaite N, et al. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet 2002;359:204-10.
389. Becker HF, Jerrentrup A, Ploch T, et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 2003;107:68-73.
390. Logan AG, Tkacova R, Perlikowski SM, et al. Refractory hypertension and sleep apnoea: effect of CPAP on blood pressure and barorefex. Eur Respir J 2003;21:241-7.
391. Babu AR, Herdegen J, Fogelfeld L, Shott S, Mazzone T. Type 2 diabetes, glycemic control, and continuous positive airway pressure in obstructive sleep apnea. Arch Intern Med 2005;165:447-52.
392. West SD, Nicoll DJ, Wallace TM, Matthews DR, Stradling JR. Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. Thorax 2007;62:969-74.
393. Eikelis N, Esler M. The neurobiology of human obesity. Exp Physiol 2005;90:673-82.
394. Tentolouris N, Liatis S, Katsilambros N. Sympathetic system activity in obesity and metabolic syndrome. Ann N Y Acad Sci 2006;1083:129-52.
395. Vincent HK, Taylor AG. Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int J Obes (Lond) 2006;30:400-18.
396. Vincent HK, Innes KE, Vincent KR. Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity. Diabetes Obes Metab 2007;9:813-39.
397. Clement K, Langin D. Regulation of infammation-related genes in human adipose tissue. J Intern Med 2007;262:422-30.
398. Haffner SM. Abdominal adiposity and cardiometabolic risk: do we have all the answers? Am J Med 2007;120:S10-6.
399. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
400. Chen J, Wildman RP, Hamm LL, et al. Association between infammation and insulin resistance in U.S. nondiabetic adults: results from the Third National Health and Nutrition Examination Survey. Diabetes Care 2004;27:2960-5.
401. Bitar MS, Al-Saleh E, Al-Mulla F. Oxidative stress--mediated alterations in glucose dynamics in a genetic animal model of type II diabetes. Life Sci 2005;77:2552-73.
402. Ge X, Yu Q, Qi W, Shi X, Zhai Q. Chronic insulin treatment causes insulin resistance in 3T3-L1 adipocytes through oxidative stress. Free Radic Res 2008;42:582-91.
403. Ogihara T, Asano T, Katagiri H, et al. Oxidative stress induces insulin resistance by activating the nuclear factor-kappa B pathway and disrupting normal subcellular distribution of phosphatidylinositol 3-kinase. Diabetologia 2004;47:794-805.
404. Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO. Refex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 1993;21:618-23.
405. Lembo G, Rendina V, Iaccarino G, Lamenza F, Volpe M, Trimarco B. Insulin reduces refex forearm sympathetic vasoconstriction in healthy humans. Hypertension 1993;21:1015-9.
406. Mooney RA, Senn J, Cameron S, et al. Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem 2001;276:25889-93.
407. Romero-Corral A, Montori VM, Somers VK, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 2006;368:666-78.
408. Kim SK, Kim HJ, Hur KY, et al. Visceral fat thickness measured by ultrasonography can estimate not only visceral obesity but also risks of cardiovascular and metabolic diseases. Am J Clin Nutr 2004;79:593-9.
409. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007;116:39-48.
410. Rosito GA, Massaro JM, Hoffmann U, et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcifcation in a community-based sample: the Framingham Heart Study. Circulation 2008;117:605-13.
411. Onat A, Avci GS, Barlan MM, Uyarel H, Uzunlar B, Sansoy V. Measures of abdominal obesity assessed for visceral adiposity and relation to coronary risk. Int J Obes Relat Metab Disord 2004;28:1018-25.
412. Pascot A, Despres JP, Lemieux I, et al. Contribution of visceral obesity to the deterioration of the metabolic risk profle in men with impaired glucose tolerance. Diabetologia 2000;43:1126-35.
413. Frayn KN. Visceral fat and insulin resistance--causative or correlative? Br J Nutr 2000;83 Suppl 1:S71-7.
414. Carmelli D, Swan GE, Bliwise DL. Relationship of 30-year changes in obesity to sleep-disordered breathing in the Western Collaborative Group Study. Obes Res 2000;8:632-7.
415. Barcelo A, Barbe F, de la Pena M, et al. Antioxidant status in patients with sleep apnoea and impact of continuous positive airway pressure treatment. Eur Respir J 2006;27:756-60.
416. Jurado-Gamez B, Martin-Malo A, Alvarez-Lara MA, Munoz L, Cosano A, Aljama P. Sleep disorders are underdiagnosed in patients on maintenance hemodialysis. Nephron Clin Pract 2007;105:c35-42.
417. Santamaria J, Iranzo A, Ma Montserrat J, de Pablo J. Persistent sleepiness in CPAP treated obstructive sleep apnea patients: evaluation and treatment. Sleep Med Rev 2007;11:195-207.
418. Wisse BE. The infammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004;15:2792-800.
419. Rankinen T, Kim SY, Perusse L, Despres JP, Bouchard C. The prediction of abdominal visceral fat level from body composition and anthropometry: ROC analysis. Int J Obes Relat Metab Disord 1999;23:801-9.
420. Despres JP. Cardiovascular disease under the infuence of excess visceral fat. Crit Pathw Cardiol 2007;6:51-9.
421. Sinski M, Lewandowski J, Abramczyk P, Narkiewicz K, Gaciong Z. Why study sympathetic nervous system? J Physiol Pharmacol 2006;57 Suppl 11:79-92.
422. Watson AM, Hood SG, May CN. Mechanisms of sympathetic activation in heart failure. Clin Exp Pharmacol Physiol 2006;33:1269-74.
423. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006;86:515-81.
424. Das UN. Hypertension as a low-grade systemic infammatory condition that has its origins in the perinatal period. J Assoc Physicians India 2006;54:133-42.
425. Di Napoli M, Papa F. Infammation, blood pressure, and stroke: an opportunity to target primary prevention? Curr Hypertens Rep 2005;7:44-51.
426. Pietropaolo M, Barinas-Mitchell E, Kuller LH. The heterogeneity of diabetes: unraveling a dispute: is systemic infammation related to islet autoimmunity? Diabetes 2007;56:1189-97.
427. Duncan BB, Schmidt MI. The epidemiology of low-grade chronic systemic infammation and type 2 diabetes. Diabetes Technol Ther 2006;8:7-17.
428. Wu TL, Chang PY, Tsao KC, Sun CF, Wu LL, Wu JT. A panel of multiple markers associated with chronic systemic infammation and the risk of atherogenesis is detectable in asthma and chronic obstructive pulmonary disease. J Clin Lab Anal 2007;21:367-71.
429. Silvestri M, Bontempelli M, Giacomelli M, et al. High serum levels of tumour necrosis factor-alpha and interleukin-8 in severe asthma: markers of systemic infammation? Clin Exp Allergy 2006;36:1373-81.
430. Yang SR, Chida AS, Bauter MR, et al. Cigarette smoke induces proinfammatory cytokine release by activation of NF-kappaB and posttranslational modifcations of histone deacetylase in macrophages. Am J Physiol Lung Cell Mol Physiol 2006;291:L46-57.
431. Andrews JO, Tingen MS. The effect of smoking, smoking cessation, and passive smoke exposure on common laboratory values in clinical settings: a review of the evidence. Crit Care Nurs Clin North Am 2006;18:63-9, xii.
432. van der Vaart H, Postma DS, Timens W, ten Hacken NH. Acute effects of cigarette smoke on infammation and oxidative stress: a review. Thorax 2004;59:713-21.
433. Piconi L, Quagliaro L, Ceriello A. Oxidative stress in diabetes. Clin Chem Lab Med 2003;41:1144-9.
434. Maritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 2003;17:24-38.
435. Kaneto H, Matsuoka TA, Katakami N, et al. Oxidative Stress and the JNK pathway are involved in the development of type 1 and type 2 diabetes. Curr Mol Med 2007;7:674-86.
436. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF. Systemic effects of smoking. Chest 2007;131:1557-66.
437. Schleicher E, Friess U. Oxidative stress, AGE, and atherosclerosis. Kidney Int Suppl 2007:S17-26.
438. Yu BP, Chung HY. Adaptive mechanisms to oxidative stress during aging. Mech Ageing Dev 2006;127:436-43.
439. Afonso V, Champy R, Mitrovic D, Collin P, Lomri A. Reactive oxygen species and superoxide dismutases: role in joint diseases. Joint Bone Spine 2007;74:324-9.
440. Mancia G, Bousquet P, Elghozi JL, et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens 2007;25:909-20.
441. Ip MS, Lam B, Ng MM, Lam WK, Tsang KW, Lam KS. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002;165:670-6.
442. Parish JM, Adam T, Facchiano L. Relationship of metabolic syndrome and obstructive sleep apnea. J Clin Sleep Med 2007;3:467-72.
443. Jordan W, Berger C, Cohrs S, et al. CPAP-therapy effectively lowers serum homocysteine in obstructive sleep apnea syndrome. J Neural Transm 2004;111:683-9.
444. Polidori MC, Stahl W, Eichler O, Niestroj I, Sies H. Profles of antioxidants in human plasma. Free Radic Biol Med 2001;30:456-62.
445. Yu BP. Cellular defenses against damage from reactive oxygen species. Physiol Rev 1994;74:139-62.
446. Rodriguez C, Mayo JC, Sainz RM, et al. Regulation of antioxidant enzymes: a signifcant role for melatonin. J Pineal Res 2004;36:1-9.
447. Cao G, Prior RL. Comparison of different analytical methods for assessing total antioxidant capacity of human serum. Clin Chem 1998;44:1309-15.
448. Hernandez C, Abreu J, Abreu P, Castro A, Jimenez A. Nocturnal melatonin plasma levels in patients with OSAS: the effect of CPAP. Eur Respir J 2007;30:496-500.
449. Ulfberg J, Micic S, Strom J. Afternoon serum-melatonin in sleep disordered breathing. J Intern Med 1998;244:163-8.
450. van Exel E, Gussekloo J, de Craen AJ, Frolich M, Bootsma-Van Der Wiel A, Westendorp RG. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes 2002;51:1088-92.
451. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765.
452. Mallat Z, Besnard S, Duriez M, et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999;85:e17-24.
453. Pinderski Oslund LJ, Hedrick CC, Olvera T, et al. Interleukin- 10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 1999;19:2847-53.
454. Kim HJ, Higashimori T, Park SY, et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 2004;53:1060-7.
455. Gozal D, Serpero LD, Sans Capdevila O, Kheirandish-Gozal L. Systemic infammation in non-obese children with obstructive sleep apnea. Sleep Med 2008;62:489-94.
456. Dyugovskaya L, Lavie P, Lavie L. Lymphocyte activation as a possible measure of atherosclerotic risk in patients with sleep apnea. Ann N Y Acad Sci 2005;1051:340-50.
457. Grote L, Kraiczi H, Hedner J. Reduced alpha- and beta(2)-adrenergic vascular response in patients with obstructive sleep apnea. Am J Respir Crit Care Med 2000;162:1480-7.
458. Mills PJ, Kennedy BP, Loredo JS, Dimsdale JE, Ziegler MG. Effects of nasal continuous positive airway pressure and oxygen supplementation on norepinephrine kinetics and cardiovascular responses in obstructive sleep apnea. J Appl Physiol 2006;100:343-8.
459. Kathiresan S, Melander O, Guiducci C, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008;40:189-97.
460. Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. N Engl J Med 2007;357:443-53.
461. Scott LJ, Mohlke KL, Bonnycastle LL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007;316:1341-5.
462. Wang SS, Schadt EE, Wang H, et al. Identifcation of pathways for atherosclerosis in mice: integration of quantitative trait locus analysis and global gene expression data. Circ Res 2007;101:e11-30.
463. Zeggini E, Weedon MN, Lindgren CM, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007;316:1336-41.
464. Zhu H, Poole J, Lu Y, et al. Sympathetic nervous system, genes and human essential hypertension. Curr Neurovasc Res 2005;2:303-17.
465. Leopold JA, Loscalzo J. Oxidative enzymopathies and vascular disease. Arterioscler Thromb Vasc Biol 2005;25:1332-40.
466. Olivieri F, Antonicelli R, Cardelli M, et al. Genetic polymorphisms of infammatory cytokines and myocardial infarction in the elderly. Mech Ageing Dev 2006;127:552-9.
467. Borgel J, Sanner BM, Bittlinsky A, et al. Obstructive sleep apnoea and its therapy infuence high-density lipoprotein cholesterol serum levels. Eur Respir J 2006;27:121-7.
468. Bostrom KB, Hedner J, Melander O, et al. Interaction between the angiotensin-converting enzyme gene insertion/deletion polymorphism and obstructive sleep apnoea as a mechanism for hypertension. J Hypertens 2007;25:779-83.
469. Lavie L, Lotan R, Hochberg I, Herer P, Lavie P, Levy AP. Haptoglobin polymorphism is a risk factor for cardiovascular disease in patients with obstructive sleep apnea syndrome. Sleep 2003;26:592-5.
470. Lin L, Finn L, Zhang J, Young T, Mignot E. Angiotensin-converting enzyme, sleep-disordered breathing, and hypertension. Am J Respir Crit Care Med 2004;170:1349-53.
471. Patel SR, Larkin EK, Mignot E, Lin L, Redline S. The association of angiotensin converting enzyme (ACE) polymorphisms with sleep apnea and hypertension. Sleep 2007;30:531-3.
472. Barcelo A, Llompart E, Barbe F, Morla M, Vila M, Agusti AG. Plasminogen activator inhibitor-I (PAI-I) polymorphisms in patients with obstructive sleep apnoea. Respir Med 2002;96:193-6.
473. Bayazit YA, Yilmaz M, Erdal E, et al. Role of nitric oxide synthase gene intron 4 and exon 7 polymorphisms in obstructive sleep apnea syndrome. Eur Arch Otorhinolaryngol 2008.
474. Diefenbach K, Kretschmer K, Bauer S, et al. Endothelin-1 gene variant lys198asn and plasma endothelin level in obstructive sleep apnea. Cardiology 2008;112:62-68.
475. Gozal D, Capdevila OS, Kheirandish-Gozal L, Crabtree VM. APOE epsilon 4 allele, cognitive dysfunction, and obstructive sleep apnea in children. Neurology 2007;69:243-9.
476. Keating BJ, Tischfeld S, Murray SS, et al. Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS ONE 2008;3:e3583.
477. Maresso K, Broeckel U. Genotyping platforms for mass-throughput genotyping with SNPs, including human genome-wide scans. Adv Genet 2008;60:107-39.
478. Morton NE. Into the post-HapMap era. Adv Genet 2008;60:727- 42.
479. Uchiyama M, Ishibashi K, Enomoto T, et al. Twenty-four hour profles of four hormones under constant routine. Psychiatry Clin Neurosci 1998;52:241-3.
480. Wyatt JK, Ritz-De Cecco A, Czeisler CA, Dijk DJ. Circadian temperature and melatonin rhythms, sleep, and neurobehavioral function in humans living on a 20-h day. Am J Physiol 1999;277:R1152-63.
481. Gilbert SS, van den Heuvel CJ, Ferguson SA, Dawson D. Thermoregulation as a sleep signalling system. Sleep Med Rev 2004;8:81-93.
482. Rasch B, Dodt C, Molle M, Born J. Sleep-stage-specifc regulation of plasma catecholamine concentration. Psychoneuroendocrinology 2007;32:884-91.
483. Mendez M, Bianchi AM, Villantieri O, Cerutti S. Time-varying analysis of the heart rate variability during REM and non REM sleep stages. Conf Proc IEEE Eng Med Biol Soc 2006;1:3576-9.
484. Bach V, Telliez F, Libert JP. The interaction between sleep and thermoregulation in adults and neonates. Sleep Med Rev 2002;6:481-92.
485. Issa FG, Sullivan CE. The immediate effects of nasal continuous positive airway pressure treatment on sleep pattern in patients with obstructive sleep apnea syndrome. Electroencephalogr Clin Neurophysiol 1986;63:10-7.
486. Loredo JS, Ancoli-Israel S, Kim EJ, Lim WJ, Dimsdale JE. Effect of continuous positive airway pressure versus supplemental oxygen on sleep quality in obstructive sleep apnea: a placebo-CPAP- controlled study. Sleep 2006;29:564-71.
487. Aldrich M, Eiser A, Lee M, Shipley JE. Effects of continuous positive airway pressure on phasic events of REM sleep in patients with obstructive sleep apnea. Sleep 1989;12:413-9.
488. Cahan C, Decker MJ, Arnold JL, Goldwasser E, Strohl KP. Erythropoietin levels with treatment of obstructive sleep apnea. J Appl Physiol 1995;79:1278-85.
489. Hashimoto S, Morohoshi K, Suzuki T, Matsushima K. Lipopolysaccharide- inducible gene expression profle in human monocytes. Scand J Infect Dis 2003;35:619-27.
490. Moore DF, Li H, Jeffries N, et al. Using peripheral blood mononuclear cells to determine a gene expression profle of acute ischemic stroke: a pilot investigation. Circulation 2005;111:212-21.
491. Tanner MA, Berk LS, Felten DL, Blidy AD, Bit SL, Ruff DW. Substantial changes in gene expression level due to the storage temperature and storage duration of human whole blood. Clin Lab Haematol 2002;24:337-41.
492. Rainen L, Oelmueller U, Jurgensen S, et al. Stabilization of mRNA expression in whole blood samples. Clin Chem 2002;48:1883-90.
493. Debey S, Schoenbeck U, Hellmich M, et al. Comparison of different isolation techniques prior gene expression profling of blood derived cells: impact on physiological responses, on overall expression and the role of different cell types. Pharmacogenomics J 2004;4:193-207.
494. Ovstebo R, Lande K, Kierulf P, Haug KB. Quantifcation of relative changes in specifc mRNAs from frozen whole blood - methodological considerations and clinical implications. Clin Chem Lab Med 2007;45:171-6.
495. Kagedal B, Lindqvist M, Farneback M, Lenner L, Peterson C. Failure of the PAXgene Blood RNA System to maintain mRNA stability in whole blood. Clin Chem Lab Med 2005;43:1190-2.
496. Kim SJ, Dix DJ, Thompson KE, et al. Effects of storage, RNA extraction, genechip type, and donor sex on gene expression profling of human whole blood. Clin Chem 2007;53:1038-45.
497. Mutter GL, Zahrieh D, Liu C, et al. Comparison of frozen and RNALater solid tissue storage methods for use in RNA expression microarrays. BMC Genomics 2004;5:88.
498. Thach DC, Lin B, Walter E, et al. Assessment of two methods for handling blood in collection tubes with RNA stabilizing agent for surveillance of gene expression profles with high density microarrays. J Immunol Methods 2003;283:269-79.
499. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-93.
500. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
501. Hariharan R. The analysis of microarray data. Pharmacogenomics 2003;4:477-97.
502. Mantini D, Petrucci F, Pieragostino D, et al. LIMPIC: a computational method for the separation of protein MALDI-TOF-MS signals from noise. BMC Bioinformatics 2007;8:101.
503. Cui X, Hwang JT, Qiu J, Blades NJ, Churchill GA. Improved statistical tests for differential gene expression by shrinking variance components estimates. Biostatistics 2005;6:59-75.
504. Kerr MK, Churchill GA. Bootstrapping cluster analysis: assessing the reliability of conclusions from microarray experiments. Proc Natl Acad Sci U S A 2001;98:8961-5.
505. Churchill GA. Fundamentals of experimental design for cDNA microarrays. Nat Genet 2002;32 Suppl:490-5.
506. Kerr MK, Churchill GA. Statistical design and the analysis of gene expression microarray data. Genet Res 2001;77:123-8.
507. Coombes KR, Morris JS, Hu J, Edmonson SR, Baggerly KA. Serum proteomics profling--a young technology begins to mature. Nat Biotechnol 2005;23:291-2.
508. Conrads TP, Hood BL, Veenstra TD. Sampling and analytical strategies for biomarker discovery using mass spectrometry. Biotechniques 2006;40:799-805.
509. Mayr M, Zhang J, Greene AS, Gutterman D, Perloff J, Ping P. Proteomics-based development of biomarkers in cardiovascular disease: mechanistic, clinical, and therapeutic insights. Mol Cell Proteomics 2006;5:1853-64.
510. Gulcicek EE, Colangelo CM, McMurray W, et al. Proteomics and the analysis of proteomic data: an overview of current proteinprofling technologies. Curr Protoc Bioinformatics 2005;Chapter 13:Unit 13 1.
511. Lee HJ, Wark AW, Corn RM. Microarray methods for protein biomarker detection. Analyst 2008;133:975-83.
512. Tammen H, Schulte I, Hess R, et al. Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics 2005;5:3414-22.
513. Soultan Z, Wadowski S, Rao M, Kravath RE. Effect of treating obstructive sleep apnea by tonsillectomy and/or adenoidectomy on obesity in children. Arch Pediatr Adolesc Med 1999;153:33-7.
514. Berliner JA, Zimman A. Future of toxicology--lipidomics, an important emerging area for toxicologists: focus on lipid oxidation products. Chem Res Toxicol 2007;20:849-53.
515. German JB, Gillies LA, Smilowitz JT, Zivkovic AM, Watkins SM. Lipidomics and lipid profling in metabolomics. Curr Opin Lipidol 2007;18:66-71.
516. Wiest MM, Watkins SM. Biomarker discovery using high-dimensional lipid analysis. Curr Opin Lipidol 2007;18:181-6.
517. Maher AD, Zirah SF, Holmes E, Nicholson JK. Experimental and analytical variation in human urine in 1H NMR spectroscopy-based metabolic phenotyping studies. Anal Chem 2007;79:5204-11.
518. Wilson ID, Plumb R, Granger J, Major H, Williams R, Lenz EM. HPLC-MS-based methods for the study of metabonomics. J Chromatogr B Analyt Technol Biomed Life Sci 2005;817:67-76.
519. Su X, Han X, Mancuso DJ, Abendschein DR, Gross RW. Accumulation of long-chain acylcarnitine and 3-hydroxy acylcarnitine molecular species in diabetic myocardium: identifcation of alterations in mitochondrial fatty acid processing in diabetic myocardium by shotgun lipidomics. Biochemistry 2005;44:5234-45.
520. Brindle JT, Antti H, Holmes E, et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 2002;8:1439-44.
521. Patel C, Ghanim H, Ravishankar S, et al. Prolonged reactive oxygen species generation and nuclear factor-kappaB activation after a high-fat, high-carbohydrate meal in the obese. J Clin Endocrinol Metab 2007;92:4476-9.
522. Ulrich C, Heine GH, Garcia P, et al. Increased expression of monocytic angiotensin-converting enzyme in dialysis patients with cardiovascular disease. Nephrol Dial Transplant 2006;21:1596-602.
523. Weisberg SP, Hunter D, Huber R, et al. CCR2 modulates infammatory and metabolic effects of high-fat feeding. J Clin Invest 2006;116:115-24.
524. Ross R. Atherosclerosis--an infammatory disease. N Engl J Med 1999;340:115-26.
525. Hansson GK. Infammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
526. Dyugovskaya L, Lavie P, Lavie L. Phenotypic and functional characterization of blood gammadelta T cells in sleep apnea. Am J Respir Crit Care Med 2003;168:242-9.
527. Dyugovskaya L, Lavie P, Hirsh M, Lavie L. Activated CD8+ T-lymphocytes in obstructive sleep apnoea. Eur Respir J 2005;25:820-8.
528. Kontogianni K, Messini-Nikolaki N, Christou K, Gourgoulianis K, Tsilimigaki S, Piperakis SM. DNA damage and repair capacity in lymphocytes from obstructive sleep apnea patients. Environ Mol Mutagen 2007;48:722-7.